Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001628280-25-021311
Filing Date
2025-05-01
Accepted
2025-05-01 07:00:42
Documents
21
Period of Report
2025-06-17

Document Format Files

Seq Description Document Type Size
1 DEF 14A avtx-20250501.htm   iXBRL DEF 14A 653591
6 GRAPHIC avtx-20250501_g1.jpg GRAPHIC 48586
7 GRAPHIC avtx-20250501_g2.jpg GRAPHIC 61527
8 GRAPHIC avtx-20250501_g3.jpg GRAPHIC 67494
9 GRAPHIC avtx-20250501_g4.jpg GRAPHIC 133840
10 GRAPHIC avtx-20250501_g5.jpg GRAPHIC 116583
  Complete submission text file 0001628280-25-021311.txt   2308388

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT avtx-20250501.xsd EX-101.SCH 2479
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT avtx-20250501_def.xml EX-101.DEF 2648
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT avtx-20250501_lab.xml EX-101.LAB 2948
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT avtx-20250501_pre.xml EX-101.PRE 1719
23 EXTRACTED XBRL INSTANCE DOCUMENT avtx-20250501_htm.xml XML 151811
Mailing Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850
Business Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850 410-522-8707
Avalo Therapeutics, Inc. (Filer) CIK: 0001534120 (see all company filings)

EIN.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37590 | Film No.: 25899335
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)